CIK 0001631574 · Large accelerated filer
Wave Life Sciences, Inc.
Sign in to watch- Ticker
- WVE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2900
- Business address
- 733 CONCORD AVENUE, CAMBRIDGE, MA, 02138
- Former names
- Wave Life Sciences Ltd., Wave Life Sciences LTD., WAVE Life Sciences Ltd., Wave Life Sciences Pte Ltd
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-05 | BOLNO PAUL President and CEO | Grant or award | +165,000 | 286,000 | ||
| 2026-02-05 | BOLNO PAUL President and CEO | Grant or award · Share Option (right to buy) | +1,000,000 | 1,000,000 | ||
| 2026-02-05 | Francis Chris See Remarks | Grant or award | +38,750 | 63,750 | ||
| 2026-02-05 | Francis Chris See Remarks | Grant or award · Share Option (right to buy) | +232,500 | 232,500 | ||
| 2026-02-05 | Vargeese Chandra See Remarks | Grant or award | +45,625 | 411,474 | ||
| 2026-02-05 | Vargeese Chandra See Remarks | Grant or award · Share Option (right to buy) | +273,750 | 273,750 | ||
| 2026-01-02 | Francis Chris See Remarks | Option exercise 10b5-1 | +9,375 | $3.14 | $29K | 34,375 |
| 2026-01-02 | Francis Chris See Remarks | Sale 10b5-1 | −8,080 | $15.92 | $129K | 26,295 |
| 2026-01-02 | Francis Chris See Remarks | Sale 10b5-1 | −1,295 | $16.70 | $22K | 25,000 |
| 2026-01-02 | Francis Chris See Remarks | Option exercise · Share Option (right to buy) 10b5-1 | −9,375 | 0 | ||
| 2025-12-11 | GSK plc 10% owner | Purchase | +1,470,000 | $19.00 | $27.9M | 18,245,691 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Option exercise 10b5-1 | +36,000 | $8.17 | $294K | 125,218 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −36 | $20.25 | $729 | 89,218 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Option exercise 10b5-1 | +50,000 | $10.48 | $524K | 139,218 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Sale 10b5-1 | −50,000 | $20.03 | $1.0M | 90,365 |
| 2025-12-09 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −36,000 | 0 | ||
| 2025-12-09 | Moran Kyle Chief Financial Officer | Grant or award · Share Option (right to buy) 10b5-1 | −50,000 | 0 | ||
| 2025-12-08 | Rawcliffe Adrian Director | Option exercise 10b5-1 | +42,000 | $5.97 | $251K | 54,700 |
| 2025-12-08 | Rawcliffe Adrian Director | Sale 10b5-1 | −42,000 | $15.00 | $630K | 12,700 |
| 2025-12-08 | Rawcliffe Adrian Director | Option exercise · Share Option (right to buy) 10b5-1 | −42,000 | 0 |
Page 3 of 13 · 255 trades